How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,156 results for

E/M Established Outpatient Visit

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3141. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis

analysis. Pediatrics 2001; 108(4): 835-844 PubMedID Other publications of related interest Baraff L, Lee S, Schriger D L. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatric Infectious Disease Journal 1993;12:389-394. Carroll W, Farrell M, Singer J, Jackson M, Lobel J, Lewis E. Treatment of occult bacteremia: a prospective randomised clinical trial. Pediatrics 1983;72:608-612. Lieu T, Schwartz S, Jaffe D, Fleisher G. Strategies for diagnosis and treatment of children at risk (...) Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis Lee G M, Fleisher G R, Harper M B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

2001 NHS Economic Evaluation Database.

3142. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?

Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Ledwidge M, Barry M, Cahill J, Ryan E, Maurer B, Ryder M, Travers B, Timmons L, McDonald K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) understanding, and salt restriction. Support comprised nurse-led care on three or more occasions through telephone contact and outpatient clinic visits. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised individuals presenting at casualty with a diagnosis of HF. The patients were at least 18 years of age. Patients presenting with HF in the setting of myocardial infarction or unstable angina, or in whom HF

2003 NHS Economic Evaluation Database.

3143. Cost-effectiveness of a targeted disinfection program in household kitchens to prevent foodborne illnesses in the United States, Canada, and the United Kingdom

A, Mafilios M S, Todd E C, Krilov L R, Geddes A M, Ackerman S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a disinfection programme targeted at household kitchens to prevent foodborne illnesses in the USA, Canada (...) describing the usual symptoms associated with each health state to the expert panel. The panellists assigned distress and disability ratings to each health state using the method developed by Rosser and Kind. The experts also assigned the average duration of each health state. Direct costs The resource quantities and the costs were not reported separately. The direct costs included in the study were those of the health care service. These were for physician office visits, outpatient and emergency room

2003 NHS Economic Evaluation Database.

3144. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain

Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain Gonzalez-Larriba J L, Serrano S, Alvarez-Mon M, Camacho F, Casado M A, Diaz-Perez J L, Diaz-Rubio E, Fosbrook L, Guillem V, Lopez-Lopez J J, Moreno-Nogueira J A, Toribio J Record Status (...) therapy in countries where other adjuvant therapies with similar costs are used to treat other types of cancer. Source of funding None stated. Bibliographic details Gonzalez-Larriba J L, Serrano S, Alvarez-Mon M, Camacho F, Casado M A, Diaz-Perez J L, Diaz-Rubio E, Fosbrook L, Guillem V, Lopez-Lopez J J, Moreno-Nogueira J A, Toribio J. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. European Journal of Cancer 2000; 36(18): 2344-2352 PubMedID Other

2000 NHS Economic Evaluation Database.

3145. Clinical practice guidelines for the psychosocial care of adults with cancer

B. Persons involved in the development of the Psychosocial clinical practice guidelines: providing information and support for women with breast cancer 127 C. Guideline development process 128 D. Incidence of cancers in Australia in 1998 137 E. Resources and contacts for patients and the treatment team 138 F . Financial assistance for travel and accommodation 149 G. Recommendations for strategies to overcome barriers to effective psychosocial referral 149 H. Services for people from culturally (...) Recommended steps for preparing patients for transition to palliative care 67 3.3A Recommended steps involved in ensuring that all people with cancer have adequate emotional and social support 70 3.3B Support sources that can improve the emotional well-being of people with cancer 73 3.5 Recommended steps for establishing continuity of care 79 3.6 Recommended steps involved in providing end of life support 84 3.7A Effective strategies/techniques that can be utilised by treatment team members to improve

2002 Cancer Australia

3146. Clinical practice guidelines for the management of advanced breast cancer

it as a reference to be used in cooperation with their doctor and other health care professionals with whom they are involved.5 Clinical practice guidelines for the management of advanced breast cancer S U M M A RY O F G U I D E L I N E S The following table provides a summary of the guidelines presented in this document. Each of the recommendations should be considered in the care and management of women with advanced breast cancer. To understand the context of this evidence, readers should turn (...) , and previous type of therapy (for example, hormone or chemotherapy). 2821 Clinical practice guidelines for the management of advanced breast cancer C H A P T E R 2 T H E I M PAC T O F A DVA N C E D B R E A S T C A N C E R 2 .1 QUA LI T Y OF LI FE A ND PS YC H OS OCI A L I SS UE S Quality of life is a multidimensional construct that is generally accepted to include several important areas or domains of a person’s life: physical functioning, psychological functioning, social functioning, sexual functioning

2000 Cancer Australia

3147. Clinical practice guidelines for the management of early breast cancer

on the woman 17 1.6 The effect on the family 18 2. General principles of care 21 2.1 Aims of treatment 21 2.2 Establishing good communication practices 22 2.3 Counselling and support 29 2.4 Choosing a specialist 32 2.5 Second opinion 34 2.6 Disclosure of risk 34 2.7 Clinical trials 35 2.8 Pregnancy 37 2.9 Complementary and alternative therapies 38 3. Before definitive treatment 41 3.1 History 42 3.2 Clinical examination 42 3.3 Investigations 43 3.4 Pathology 47iv Clinical practice guidelines (...) Clinical practice guidelines for the management of early breast cancer Appendices A. Development of the first edition (1995) 111 B. Revision of the first edition (1995) and production of the second edition (2001) 121 C. TNM clinical classification 139 D. RACOG Bulletin Vol 10, No 1, May 1996 (working party on tamoxifen and the endometrium) 141 E. Questions you may be asked 145 F. iSource National Breast Cancer Centre Publications List 149 G. Types of clinical trials 153 H. Breast cancer support

2001 Cancer Australia

3148. Clinical practice guidelines for the psychosocial care of adults with cancer

B. Persons involved in the development of the Psychosocial clinical practice guidelines: providing information and support for women with breast cancer 127 C. Guideline development process 128 D. Incidence of cancers in Australia in 1998 137 E. Resources and contacts for patients and the treatment team 138 F . Financial assistance for travel and accommodation 149 G. Recommendations for strategies to overcome barriers to effective psychosocial referral 149 H. Services for people from culturally (...) Recommended steps for preparing patients for transition to palliative care 67 3.3A Recommended steps involved in ensuring that all people with cancer have adequate emotional and social support 70 3.3B Support sources that can improve the emotional well-being of people with cancer 73 3.5 Recommended steps for establishing continuity of care 79 3.6 Recommended steps involved in providing end of life support 84 3.7A Effective strategies/techniques that can be utilised by treatment team members to improve

2003 National Breast and Ovarian Cancer Centre

3149. [Assessment of an electronic referral and teleconsultation system between secondary and primary health care]

E, Paavola T, Carlson C, Viikinkoski P, Bockerman M, Kaariainen P, Ohinmaa A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Harno K, Arajarvi E, Paavola T, Carlson C, Viikinkoski P, Bockerman M, Kaariainen P, Ohinmaa A. Etapoliklinikan arviointi - Peijaksen etapoliklinikkaprojektin loppuraportti. [Assessment of an electronic referral (...) and teleconsultation system between secondary and primary health care] Helsinki: Finnish Office for Health Care Technology Assessment (FinOHTA). FinOHTA Report No. 10. 1999 Authors' objectives The aim of this study was firstly to examine the ability of telemedicine supported outpatient clinics in Peijas Hospital to improve and replace present health care chains and, secondly, to compare the computer supported outpatient clinical model with outpatient clinics in Hyvinkaa hospital lacking these facilities and also

1999 Health Technology Assessment (HTA) Database.

3151. Risk Assessment and Prevention of Pressure Ulcers

implementation! Doris Grinspun, RN, MSN, PhD(cand), OOnt Executive Director Registered Nurses’ Association of Ontario1 Nursing Best Practice Guideline Program Team: Tazim Virani, RN, MScN, PhD(candidate) Program Director Heather McConnell, RN, BScN, MA(Ed) Program Manager Stephanie Lappan-Gracon, RN, MN Program Coordinator – Best Practice Champions Network Josephine Santos, RN, MN Program Coordinator Jane M. Schouten, RN, BScN, MBA Program Coordinator Bonnie Russell, BJ Program Assistant Carrie Scott (...) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 Appendix C: Braden Scale for Predicting Pressure Sore Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 Appendix D: Risk and Related Interventions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Appendix E: Staging of Pressure Ulcers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Appendix F: Pressure Reduction and Pressure

2002 Registered Nurses' Association of Ontario

3152. Predicting the future: Can this patient with acute congestive heart failure be safely discharged from the emergency department?

failure be safely discharged from the emergency department? x Margaret Hsieh , MD , x Thomas E. Auble , PhD , x Donald M. Yealy , MD Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA. DOI: | Figure. List of major inhospital complications in the 1996 study by Chin et al. x 10 Chin, M and Goldman, L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med . 1996 ; 156 : 1814–1820 | | Hide Pane Expand all (...) complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med . 1996 ; 156 : 1814–1820 | | , x 11 Chin, M and Goldman, L. Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol . 1997 ; 79 : 1640–1644 | | | | | and 1 study of both inpatients and outpatients x 12 Cowie, MR, Wood, DA, Coats, AJS et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000 ; 83 : 505–510

2002 Evidence-Based Emergency Medicine

3153. How good is a negative cranial computed tomographic scan result in excluding subarachnoid hemorrhage?

is recommended by most physicians in the situation of a patient with an acute, severe headache, normal neurologic examination, and normal CT findings. x 3 Edlow, J and Caplan, L. Pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl J Med . 2000 ; 342 : 29–36 | | | , x 4 Mayberg, MR, Batjer, HH, Dacey, R et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke . 1994 ; 25 : 2315–2328 | | | , x 5 Vermeulen, M. Subarachnoid haemorrhage: diagnosis and treatment. J Neurol . 1996 (...) ; 243 : 496–501 | | | , x 6 Vermeulen, M and van Gijn, J. The diagnosis of subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry . 1990 ; 53 : 365–372 | | | The CSF is examined for blood and xanthochromia. Ideally, you would like to see a study that performs LP in all patients being evaluated for SAH—those with both negative and positive CT scan findings. However, in reality, because of the practice convention alluded to above, you think it unlikely that you will find a study in which LP has been

2000 Evidence-Based Emergency Medicine

3154. A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Participant has a BMI less than or equal to 42 kg/m^2 at the screening visit Participant has been diagnosed with Type 2 Diabetes that is being treated either (...) orally from 20 mg to 120 mg per dose over a multiple dosing period. Experimental: MK-1006 120 mg Once Daily (Panel D) After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU. Drug: MK-1006 MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period. Experimental: MK-1006 20 mg Twice Daily (Panel E) After a 2-week run-in/wash-off

2008 Clinical Trials

3155. Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

; G-CSF will be continued until the patient's white blood cell count has returned to normal levels. Patients will remain closely monitored either in the outpatient clinic setting or in the hospital for approximately 2-3 months after the transplant, but possibly longer if there are complications. Follow-up study visits will occur at 6 months and then at 1, 2, 3, 4, and 5 years after the transplant. Study researchers will keep track of the patient's medical condition after leaving the transplant (...) can be safely established with reduced intensity conditioning followed by matched sibling or unrelated donor bone marrow transplantation in patients with severe SSc. OUTLINE: Patients receive fludarabine phosphate intravenously (IV) on days -6, -5, -4, -3 and -2 and Cyclophosphamide IV on days -6, -5, and undergo 2 Gray TBI on day -1. Patients receive human leukocyte antigen (HLA)-matched donor bone marrow transplantation on day 0. Patients then receive cyclophosphamide IV on days +3 and +4

2008 Clinical Trials

3156. Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis

Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis Wootton R, Bloomer S E, Corbett R (...) , Eedy D J, Hicks N, Lotery H E, Mathews C, Paisley J, Steele K, Loane M A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Real time teledermatology in general practice patients requiring referral to dermatology services. Standard

2000 NHS Economic Evaluation Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>